Sponsors (2)
The bill strengthens FDA enforcement to reduce unsafe or mislabeled dietary supplements and improve consumer safety, but does so at the cost of higher compliance burdens for small producers and potential supply disruptions or price increases for consumers.
Low-income consumers will be less likely to purchase products mislabeled as dietary supplements, reducing exposure to unregulated or unsafe substances and improving public health safety.
Consumers may experience disrupted availability of some supplement products and upward price pressure if items prepared with the participation of debarred persons are barred from import or sale.
Importers and small supplement manufacturers will face higher compliance costs and risk lost inventory from increased FDA refusals or seizures, imposing financial strain on small-business owners.
Based on analysis of 2 sections of legislative text.
Introduced February 5, 2026 by Richard Joseph Durbin · Last progress February 5, 2026
Prohibits selling or importing products represented as dietary supplements if they do not meet the federal definition of a “dietary supplement,” and bans sale or import of dietary supplements that were prepared, packed, or held with the assistance of a person debarred by the FDA. It also expands FDA enforcement authority to refuse admission at the border and to seize such articles under existing FD&C Act tools. The changes insert two new prohibited acts into the Federal Food, Drug, and Cosmetic Act and update the statutes that govern import exclusion and seizure so FDA can use those authorities for products covered by the new prohibitions. The law affects manufacturers, distributors, importers, and retailers of dietary supplements and clarifies regulatory reach over products that are misrepresented or tied to debarred individuals.